美国医疗保险和医疗补助服务中心（CMS）近日公布了第三轮药品价格谈判的选定药物名单。此次入围的药品包括用于慢性阻塞性肺病的安诺罗易利达（Anoro Ellipta）、治疗艾滋病的必克特维（Biktarvy）、以及广泛应用于医疗与美容领域的保妥适（Botox）和保妥适美容针（Botox Cosmetic）。此外，自身免疫疾病治疗药物辛齐亚（Cimzia）与科森提斯（Cosentyx）也成功入选。
本轮谈判旨在通过协商降低联邦医疗保险（Medicare）计划支付的药品价格，以减轻参保人的经济负担。上述药物的选择基于其在医保支出中的较高占比及缺乏市场竞争的现状。谈判结果预计将对相关制药企业的市场策略与收入产生显著影响。
下一步，CMS将与企业就药品价格进行直接协商，最终谈判价格将于2024年公布。此举被视为美国控制医疗成本上涨的关键措施之一。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.